Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

FcRn inhibitors

Immunology

Immunology Today—March 4, 2026

This week's Immunology update covers key regulatory actions, clinical trial…

Immunology

Immunology Today — October 29, 2025

This week’s immunology update spotlights key developments, regulatory…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

Tags

AAV exit abbvie ventures Alzheimer’s blood test ANGPTL3 apixaban Arcutis Biktarvy biomarin pharmaceutical Chiesi CNS therapeutics DB-OTO Diagonal Therapeutics Drug discovery AI Eisai Factor Bioscience FcRn inhibitors genome editing GM1 gangliosidosis Hello Heart hepatitis C HER2-positive breast cancer hypotension IAS 2025 IDH1-mutant glioma Ildong oral GLP-1 Infinity influenza innovative designs Ixo-vec gene therapy licensing deals MedMobile modifiable risk factors Neuromuscular disorders PCSK9 inhibitor Pediatric-onset MS Pivekimab Sunirine Quotient Therapeutics RNAi RPDD SkinVision Sonrotoclax Staphylococcus aureus vaccine Tavapadon TB integration UTOpia bioartificial liver

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026
Lucid Diligence Brief: Gilead Sciences to acquire Ouro Medicines
Oncology Today—March 23, 2026

TAGS

AAV exit abbvie ventures Alzheimer’s blood test ANGPTL3 apixaban Arcutis Biktarvy biomarin pharmaceutical Chiesi CNS therapeutics DB-OTO Diagonal Therapeutics Drug discovery AI Eisai Factor Bioscience FcRn inhibitors genome editing GM1 gangliosidosis Hello Heart hepatitis C HER2-positive breast cancer hypotension IAS 2025 IDH1-mutant glioma Ildong oral GLP-1 Infinity influenza innovative designs Ixo-vec gene therapy licensing deals MedMobile modifiable risk factors Neuromuscular disorders PCSK9 inhibitor Pediatric-onset MS Pivekimab Sunirine Quotient Therapeutics RNAi RPDD SkinVision Sonrotoclax Staphylococcus aureus vaccine Tavapadon TB integration UTOpia bioartificial liver

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy